<DOC>
	<DOC>NCT00867698</DOC>
	<brief_summary>The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.</brief_summary>
	<brief_title>AST-120 Used to Treat Mild Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<criteria>1. Confirmed cirrhosis of any cause 2. Abnormal RBANS global summary score 3. Grade 0 or 1 hepatic encephalopathy by WestHaven Scale 4. MELD score &lt; or = 25 5. Females must be postmenopausal, surgically incapable of bearing children or practicing a reliable method of birth control 1. Previous participation in any trial involving AST120 2. History of TIPS or surgically created portocaval shunt 3. Treatment for overt HE within the past 3 months 4. Use of lactulose, rifaximin, neomycin or other antibiotics in the past 7 days 5. Active alcohol abuse 6. Psychosis or organic brain syndromes due to alcohol or other causes 7. Use of interferon and sedating or cognitionaltering drugs 8. Undergoing chemotherapy or radiotherapy for the treatment of cancer 9. Active GI bleeding within the past 3 months 10. Presence of an active infection 11. Presence of signs and symptoms of severe dehydration 12. Other major physical or major psychiatric illness within the past 6 months 13. Pregnant, breast feeding, or planning to become pregnant during the study 14. Using hormonal contraception as the only method of birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Hepatic encephalopathy</keyword>
	<keyword>Mild hepatic encephalopathy</keyword>
	<keyword>HE</keyword>
	<keyword>MHE</keyword>
	<keyword>Cognitive impairment</keyword>
	<keyword>Cognitive dysfunction</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>